title: [Use of mitoxantrone in early multiple sclerosis with malignant disease course. Observational study in 30 patients with clinical and MRI outcomes after one year].
abstract: BACKGROUND
  In an observational multicenter study, we analyzed retrospectively 30 patients with malignant form of multiple sclerosis (MS) treated with mitoxantrone the year following the first neurological event.
  
  
  METHODS
  The 30 patients were selected according to Weinshenker criteria of malignant MS (either a "catastrophic" relapse or a quickly aggressive form). We compared clinical and MRI findings the year before with the year following mitoxantrone onset treatment: annualized relapse rates (ARR), EDSS score and percentage of patients with gadolinium enhancing lesions on MRI.
  
  
  RESULTS
  A total of 87 relapses were observed in the 5.7 months before and 10 during the year following onset of mitoxantrone treatment. The ARR decreased by 95% (6.0+/-2 before and 0.3+/-0.7 after). Twenty-four patients (80%) were relapse-free one year after onset of mitoxantrone treatment. The EDSS score improved in 87% of MS patients and the mean EDSS decreased by 1.9. Ninety-seven percent had at least gadolinium enhancing lesions before the start of mitoxantrone treatment as compared to 17% after.
  
  
  CONCLUSIONS
  In our experience, mitoxantrone had a rapid and strong impact on the malignant forms of MS with a short disease duration. In this MS subgroup, mitoxantrone should be considered as an early treatment option.
authors.affiliation: Service de neurologie, hôpital Pontchaillou, rue Henri-Le-Guilloux, 35033 Rennes cedex, France. sophieory@yahoo.com
authors.forename: S
authors.initials: S
authors.lastname: Ory
authors.forename: M
authors.initials: M
authors.lastname: Debouverie
authors.forename: E
authors.initials: E
authors.lastname: Le Page
authors.forename: J
authors.initials: J
authors.lastname: Pelletier
authors.forename: I
authors.initials: I
authors.lastname: Malikova
authors.forename: O
authors.initials: O
authors.lastname: Gout
authors.forename: E
authors.initials: E
authors.lastname: Roullet
authors.forename: P
authors.initials: P
authors.lastname: Vermersch
authors.forename: G
authors.initials: G
authors.lastname: Edan
mesh_terms: D000328:Adult; D018450:Disease Progression; D005260:Female; D005682:Gadolinium; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D008942:Mitoxantrone / Q000627:therapeutic use*; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000473:pathology; D012189:Retrospective Studies; D055502:Secondary Prevention; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D007166:Immunosuppressive Agents; D005682:Gadolinium; D008942:Mitoxantrone